Brief: Trevi Therapeutics Announces Initiation Of Phase 2a RIVER Clinical Trial Of Haduvio For Refractory Chronic Cough
02/11/2023 11:44
Nov 2 (Reuters) - Trevi Therapeutics Inc TRVI.O :
* TREVI THERAPEUTICS ANNOUNCES THE INITIATION OF ITS PHASE
2A
RIVER CLINICAL TRIAL OF HADUVIO™ FOR REFRACTORY CHRONIC COUGH
* TREVI THERAPEUTICS INC - RIVER TOPLINE DATA EXPECTED IN
SECOND
HALF OF 2024
Source text for Eikon: ID:nPnmbl8Wa
Further company coverage: TRVI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Trevi Therapeutics
See all newsTrevi Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Trevi Therapeutics Q2 net loss widens on higher R&D costs
Brief: Trevi Therapeutics Q2 Net Income USD -17.797 Million
Trevi Therapeutics Q1 net loss widens as R&D costs rise
Brief: Trevi Therapeutics Q1 Net Income USD -13.192 Million